The tumor microenvironment is a dominant force in multidrug resistance.
about
CRIF1 interacting with CDK2 regulates bone marrow microenvironment-induced G0/G1 arrest of leukemia cellsPreclinical Data on Efficacy of 10 Drug-Radiation Combinations: Evaluations, Concerns, and RecommendationsMesenchymal stem cells as a vector for the inflammatory prostate microenvironmentCellular Biomechanics in Drug Screening and Evaluation: MechanopharmacologyMechanical stress impairs mitosis progression in multi-cellular tumor spheroidsThe role of tumor microenvironment in therapeutic resistanceNANOMEDICINE: will it offer possibilities to overcome multiple drug resistance in cancer?A systematic review on in vitro 3D bone metastases models: A new horizon to recapitulate the native clinical scenario?Exploring the tumor microenvironment with nanoparticlesNanostructured platforms for the sustained and local delivery of antibiotics in the treatment of osteomyelitisOvarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypesEvolutionary foundations for cancer biologyImpact of the physical microenvironment on tumor progression and metastasisQuantitative Analysis of the Cellular Microenvironment of Glioblastoma to Develop Predictive Statistical Models of Overall Survival.Interstitial fluid flow in cancer: implications for disease progression and treatment.Architecture of Chimeric Spheroids Controls Drug Transport.Targeting cellular and microenvironmental multidrug resistance.Bone-in-culture array as a platform to model early-stage bone metastases and discover anti-metastasis therapiesSialylation facilitates self-assembly of 3D multicellular prostaspheres by using cyclo-RGDfK(TPP) peptide.Microenvironmental regulation of therapeutic response in cancermicroRNA-200a-3p increases 5-fluorouracil resistance by regulating dual specificity phosphatase 6 expression.Three-dimensional in vitro tumor models for cancer research and drug evaluation.Impact of bone marrow stromal cells on Bcl-2 family members in chronic lymphocytic leukemia.The need for complex 3D culture models to unravel novel pathways and identify accurate biomarkers in breast cancerExpression of executioner procaspases and their activation by a procaspase-activating compound in chronic lymphocytic leukemia cellsIncreased adipogenesis of human adipose-derived stem cells on polycaprolactone fiber matrices.Resolving breast cancer heterogeneity by searching reliable protein cancer biomarkers in the breast fluid secretome.Combination of bortezomib and mitotic inhibitors down-modulate Bcr-Abl and efficiently eliminates tyrosine-kinase inhibitor sensitive and resistant Bcr-Abl-positive leukemic cells.Membranous expressions of Lewis y and CAM-DR-related markers are independent factors of chemotherapy resistance and poor prognosis in epithelial ovarian cancer.Quantitative high throughput screening using a primary human three-dimensional organotypic culture predicts in vivo efficacy.Extensive rewiring of epithelial-stromal co-expression networks in breast cancerAutophagy Protects from Trastuzumab-Induced Cytotoxicity in HER2 Overexpressing Breast Tumor Spheroids.Formation of stable small cell number three-dimensional ovarian cancer spheroids using hanging drop arrays for preclinical drug sensitivity assays.Microarray profiling shows distinct differences between primary tumors and commonly used preclinical models in hepatocellular carcinoma.Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp.Comprehensive Two- and Three-Dimensional RNAi Screening Identifies PI3K Inhibition as a Complement to MEK Inhibitor AS703026 for Combination Treatment of Triple-Negative Breast Cancer.Physical Intimacy of Breast Cancer Cells with Mesenchymal Stem Cells Elicits Trastuzumab Resistance through Src ActivationNew mouse xenograft model modulated by tumor-associated fibroblasts for human multi-drug resistance in cancer.Bioengineered tumors.An "elite hacker": breast tumors exploit the normal microenvironment program to instruct their progression and biological diversity.
P2860
Q24336990-1B34531D-8D50-49B8-BCD8-C767379BF299Q26767798-1642E399-7DF5-49D4-A933-F11B413EFC27Q26853374-B336B9CA-237A-42CC-9EB9-935AFC9F1706Q27021118-066F9D65-9F04-449F-8D0D-E35E2A312062Q27301931-3DDDF4C6-5793-45AF-91DC-B8E38C910EEFQ28069049-23603152-6239-47E9-9584-ADB5CE9D42DCQ28078448-CA60A3ED-B674-4A56-B18F-5E21FCA6DC62Q28080089-97770492-8FD3-431A-9F74-8D6A157764C3Q28082374-1BC5F24E-3C53-43BC-914D-A013746FFD6FQ28086953-3F5D98AC-E4D1-4C7B-B008-21EC88850FEEQ28543021-0116D1AF-7787-484F-BEAE-1BFA6FE654BEQ28709090-345683D0-17C9-4835-A320-6F84A48B0EDBQ29299789-34E44813-DCA8-4C01-8508-D77833919B06Q30275479-BDA75609-7931-4633-8515-E657248FC989Q30411142-6C70898A-BCB3-42D2-ADBA-78BAF2A016D7Q30661839-31C6F365-86A6-4AE4-8E60-502F9282A0E4Q33602284-738A398B-4533-499D-A474-5EAB787B7F0AQ33628894-591F32B8-B564-4264-9699-132740F5C68BQ33650423-C6BC7432-2FC0-4113-AB48-13F657D2F385Q33654609-13CEA6FB-A5C2-41F2-97B3-DFCC1B31A6CFQ33754032-45E68A60-7F34-48CC-B236-0F91E18DF676Q34225333-4EBADBB6-2F0E-442A-9456-543A04F9A14AQ34231324-1335725B-7F05-41A7-B537-5723EA045B86Q34291977-465F3BDA-5EA5-41B0-B29D-5826E632DC6DQ34455521-7AA33F18-4197-4CE5-B626-A1105B8914DDQ34566523-C4651346-0201-4B45-A400-C1D63C0699A4Q34815370-139201C5-CADC-4036-9C64-13B882BAF814Q35025461-3E09DD54-AB3C-4511-AE6E-E21A763FF2A6Q35402326-E0A398C2-1239-40AB-924A-102808010DCFQ35592860-3AF507DC-77F9-471A-9495-8652389ABB19Q35667722-36243111-8D39-4564-9727-9222351F6B20Q35770542-339A446E-8631-427D-8E9E-4E5A3467F9A5Q35780059-3FCF2F4A-E19F-4FDD-AADD-8C92F2C42FEBQ35828338-1E0E7412-1275-44DD-B99D-3FCE2CAC97A8Q35852614-ECE6F7C3-41A8-4701-B9D3-70F311ECB498Q35861891-B3E90CBF-1EAA-4A55-AB37-CDD69AD0D6A8Q36034029-3CBF5CA7-193E-4524-99F3-C7969015399EQ36094989-B15A1AB6-3364-4CF7-9010-C9140698ABBBQ36147620-AEF47258-CAAD-4036-9B41-6958BB4FB231Q36187733-AA6110FD-089B-4355-A170-6E5CB9B356E2
P2860
The tumor microenvironment is a dominant force in multidrug resistance.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
The tumor microenvironment is a dominant force in multidrug resistance.
@en
type
label
The tumor microenvironment is a dominant force in multidrug resistance.
@en
prefLabel
The tumor microenvironment is a dominant force in multidrug resistance.
@en
P2860
P1476
The tumor microenvironment is a dominant force in multidrug resistance
@en
P2093
Mina J Bissell
P2860
P356
10.1016/J.DRUP.2012.01.006
P577
2012-02-13T00:00:00Z